Please “Eat me”: Can Magrolimab Put Higher-risk MDS Back on the Immunologic Menu?
Open Access
- 30 May 2021
- journal article
- Published by American Society of Hematology in The Hematologist
- Vol. 18 (4)
- https://doi.org/10.1182/hem.v18.4.2021410
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b ResultsBlood, 2019
- Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid LeukemiaBlood, 2018
- Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117Journal of Clinical Oncology, 2017
- Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromesCancer, 2017
- Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic PotentialPLOS ONE, 2015
- Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905Journal of Clinical Oncology, 2014
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid PhagocytosisCell, 2009
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem CellsCell, 2009
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyThe Lancet Oncology, 2009
- Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group BJournal of Clinical Oncology, 2002